Adrian Ortiz
Executive Director, Process Research and Development Eli Lilly & Co.
Adrian Ortiz is currently an Executive Director at Eli Lilly with a focus on Early Phase Pipeline Advancement, Innovative Route Selection, and Biocatalysis. Prior to his current role he held leadership positions of increasing responsibility at Bristol Myers Squibb (2010-2019) and Amgen (2019-2025). He obtained a bachelor’s degree at the University of Arizona (2004) and a PhD at the Scripps Research Institute (TSRI, 2009) under the guidance of Professor K.C. Nicolaou.
Seminars
Wednesday 30th September 2026
Roundtable: Overcoming IP Barriers to Enable Data Sharing & Accelerate Innovation in Biocatalysis
2:40 pm
- Discuss practical approaches to balancing data sharing with protection of proprietary information
- Share experiences on collaborating with external partners while maintaining competitive advantage
- Identify actionable solutions to unlock data access without compromising commercial interests
Thursday 1st October 2026
Panel: Embedding Biocatalysis Upstream, When Does It Add Value & How Do You Make It Stick?
12:10 pm
- When is the right stage to introduce biocatalysis in the development pipeline?
- How are organizations balancing early investment with high attrition risk?
- What has worked (and failed) when trying to shift from late-stage to early-stage adoption?
- How do you align chemists, biologists, and process teams around a shared approach?
